At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Midodrine hydrochloride +1 moredrug
Likely dose
Midodrine hydrochloride 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Blind, Randomized, Placebo-controlled, Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Subjects With Moderate to Severe Neurogenic Orthostatic Hypotension
In Brief
A Phase 4 clinical trial evaluating Midodrine hydrochloride and Placebo for Hypotension, Orthostatic. Completed, enrolled 24 participants across 11 sites.
Detailed Summary
The purpose of this clinical study is to evaluate the clinical effect of midodrine hydrochloride (ProAmatine®) compared to placebo in patients with orthostatic hypotension by measuring the time to onset of near syncopal symptoms and assessing several cardiovascular measurements, such as heart rate, blood pressure, and ECG, using the tilt table test.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypotension, Orthostatic
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
Primary CompletionMar 2005
First PostedNov 2007
TodayJul 2026
First PostedNov 9, 2007
Enrollment StartSep 8, 2004
Primary CompletionMar 21, 2005
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.6 years ago
Interventions
Midodrine hydrochloridedrug
one dose, 10-30mg, given orally
Placebodrug
Placebo